Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinomaSunisa Prasopporn(Siriraj Hospital), Siwanon Jirawatnotai(Siriraj Hospital)Frontiers in OncologyNovember 30, 202210.3389/fonc.2022.1021632Cited by 12SaveCiteExport RISWatch citationsRelated PapersEstablishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies|Scientific Reports|2025|1